MORGAN STANLEY PLC/CALL/MODERNA/165/0.1/20.12.24 | Market Closed - Börse Stuttgart 03:50:22 2024-07-16 pm EDT | ||
| 0.89 EUR | +9.88% |
|
| Current month | +36.92% | ||
| 1 month | -35.97% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 0.89 | +9.88% |
| 24-07-15 | 0.81 | 0.00% |
| 24-07-12 | 0.81 | -6.90% |
| 24-07-11 | 0.87 | +20.83% |
| 24-07-10 | 0.72 | +5.88% |
Delayed Quote Börse Stuttgart
Last update July 16, 2024 at 03:50 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Morgan Stanley |
| WKN | MB32JT |
| ISIN | DE000MB32JT2 |
| Date issued | 2023-02-01 |
| Strike | 165 $ |
| Maturity | 2024-12-20 (157 Days) |
| Parity | 10 : 1 |
| Emission price | 6.9 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.18 € |
|---|---|
| Lowest since issue | 0.209 € |
| Spread | 0.05 € |
| Spread % | 5.21% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
125.1
USD
Average target price
145.9
USD
Spread / Average Target
+16.59%
- Stock Market
- Warrants
- Warrant
